ClinicalTrials.gg
RecruitingNCT07189624ECHEFUpdated Nov 9, 2026

Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma

An interventional study of Exercise in Cirrhosis With Hepatocellular Carcinoma, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Carcinoma, Hepatocellular with a site in France — 54 open to participants now, 85 under way, 14 of them phase 3. Carcinoma, Hepatocellular · France.

Planned enrollment
202nd of 215
12 · median 136
Started
2026
with 7 others
No phase
56 of 284
19 open now
Primary completion
2028-04
later than 57 of 84 live
Registered
277th of 284
by date

Among the 284 studies in Carcinoma, Hepatocellular with a site in France, this one is the 202nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 8 that started in 2026, is one of 56 with no phase, reaches primary completion later than 57 of the 84 other live ones, and was the 277th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

54 of the 284 studies in Carcinoma, Hepatocellular with a site in France are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Carcinoma, Hepatocellular with a site in France, or all of them as a file.
02

Study summary

The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.

03

Conditions studied

  • Cirrhosis With Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hepatocellular carcinoma developed on cirrhosis
  • Cirrhosis of any etiology, defined by a liver elasticity measurement >15kPa or a history of cirrhosis decompensation
  • Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
  • scores A and B7
  • WHO score ≤ 2
  • Affiliation to french national social security system

Exclusion criteria

Exclusion Criteria:

  • Hepatic encephalopathy grade II or higher
  • Bone
  • Surgery performed within 30 days prior to inclusion visit
  • Liver transplant
  • Muscle injury within 3 months of inclusion
  • Pregnant or breast-feeding women
  • Patients under legal protection (guardianship, curatorship, safeguard of justice)
  • Participation in another clinical trial within 10 days of inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Single arm

    A single study visit will be required, during which the following will be caried out: * an assessment of physical condition: lower limb isometric strength test, liver frailty index, short physical performance battery, ultrasound assessment of quadriceps muscle mass * a 30-minutes exercise session on a bicycle (with heart rate monitor and gas exchange analyzer) * 3 fasting blood tests (before, at the end and 1 hour after the exercise) to assess the production of hepatokines and metabolites * measurements of perceived fatigue, muscle pain and effort (before, at the end and 1 hour after the exercise). Snacks will be served afterwards.

    Other: Exercise

Interventions

  • OtherExercise

    30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.

06

What researchers measure

Primary outcomes

  1. Systemic hepatokines rates (FGF-21 and follistatin)

    Blood samples

    Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise

Secondary outcomes

  1. Muscle pain assessment

    Visual analog scale. Score from 0 (total absence of muscle pain) to 10 (maximum muscle pain).

    Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise

Other outcomes

  1. Fatigue assessment

    Visual analog scale. Score from 0 (total absence of fatigue) to 10 (maximum fatigue).

    Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise

  2. Perception of effort assessment

    Borg scale

    Time frame: Baseline (at the beginning), periprocedural (middle of exercise), immediately after exercise

  3. Production of metabolites

    Blood samples

    Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 21 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 21 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jul 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
Sep 24, 2025
StartActual
Jul 21, 2026was Dec 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
Show 2 sites
  • Chu Estaing Medecine Digestive Et Hepatobiliaire · Clermont-Ferrand, Franceno status→Not yet recruiting
  • CHU de Clermont-Ferrand · Clermont-Ferrand, Franceno status→Recruiting
Nov 9, 2026
Start date
Dec 2025→Jul 21, 2026 (actual)
Nov 9, 2026
Eligibility
Maximum age 75 Years→80 Years
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • Chu Estaing Medecine Digestive Et Hepatobiliaire · Clermont-Ferrand, Franceno status→Not yet recruiting
    • CHU de Clermont-Ferrand · Clermont-Ferrand, Franceno status→Recruiting
    Start date Dec 2025→Jul 21, 2026 (now actual)
    Eligibility Maximum age 75 Years→80 Years
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07189624
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Jul 21, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
0473754963

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion